Crossmark

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer

Crossref DOI link: https://doi.org/10.1038/s41467-020-18442-4

Published Online: 2020-09-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Rong http://orcid.org/0000-0002-0465-9561
Yamada, Tadaaki http://orcid.org/0000-0002-6945-281X
Kita, Kenji http://orcid.org/0000-0002-4622-6633
Taniguchi, Hirokazu http://orcid.org/0000-0003-2414-8344
Arai, Sachiko

Fukuda, Koji

Terashima, Minoru http://orcid.org/0000-0002-5688-5181
Ishimura, Akihiko http://orcid.org/0000-0002-3127-0404
Nishiyama, Akihiro

Tanimoto, Azusa http://orcid.org/0000-0002-6643-3867
Takeuchi, Shinji http://orcid.org/0000-0002-3779-1454
Ohtsubo, Koshiro

Yamashita, Kaname

Yamano, Tomoyoshi http://orcid.org/0000-0001-8849-6239
Yoshimura, Akihiro http://orcid.org/0000-0002-3753-2110
Takayama, Koichi

Kaira, Kyoichi http://orcid.org/0000-0001-5548-7686
Taniguchi, Yoshihiko http://orcid.org/0000-0001-6387-3683
Atagi, Shinji http://orcid.org/0000-0003-1876-7069
Uehara, Hisanori

Hanayama, Rikinari http://orcid.org/0000-0003-2102-3386
Matsumoto, Isao http://orcid.org/0000-0002-3335-1013
Han, Xujun http://orcid.org/0000-0002-4049-4039
Matsumoto, Kunio http://orcid.org/0000-0002-6532-4482
Wang, Wei http://orcid.org/0000-0001-8887-8499
Suzuki, Takeshi

Yano, Seiji http://orcid.org/0000-0002-6151-2988
Funding

Funding for this research was provided by:

Japan Agency for Medical Research and Development (16cm0106513h0001)

MEXT | Japan Society for the Promotion of Science (JP16H05308)

Research grants from Boehringer-Ingelheim, Eisai, and MSD, and Extramural Collaborative Research Grant of Cancer Research Institute, Kanazawa University.
License Information

Text and Data Mining valid from 2020-09-14

Version of Record valid from 2020-09-14
More Information

Article History

Received: 26 December 2019

Accepted: 24 August 2020

First Online: 14 September 2020

Competing interests

: Y.T. obtained honoraria from Chugai Pharma, AstraZeneca, and Boehringer-Ingelheim. T. Yamada obtained research grants from Ono Pharma, Chugai Pharma, Pfizer Co, and Takeda Pharma. K. Kaira obtained research grants from AstraZeneca, and honoraria from Ono Pharma, Eli Lilly, Chugai Pharma, AstraZeneca, and Boehringer-Ingelheim. S.A. obtained grants and personal fees from Chugai, grants and non-financial support from F. Hoffmann-La Roche, grants and personal fees from Boehringer Ingelheim, grants and personal fees from AstraZeneca. S.Y. obtained research grants and honoraria from Chugai Pharma, AstraZeneca, and Boehringer-Ingelheim. The other authors have no conflict of interest.

Document is current

Any future updates will be listed below